Switzerland-based AC Immune SA has appointed Nuno Mendonça as chief medical officer, effective 1 October, to help advance the company’s candidate products for neurodegenerative diseases. Dr Mendonça was previously CMO of Bial Holding SA in Portugal where he led early and late-stage development programmes across neuroscience and orphan diseases. Prior to this, he held senior positions in neuroscience at AbbVie Inc. Separately, at Novartis, he led late-stage clinical development of Zolgensma, a gene therapy for spinal muscular atrophy.
Dr Mendonça, a certified neurologist, obtained his medical degree from the University of Coimbra in Portugal.
AC Immune announced the appointment on 26 July 2023.
Copyright 2023 Evernow Publishing Ltd